FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2059583192> ?p ?o ?g. }

• W2059583192 endingPage "3542" @default.
• W2059583192 startingPage "3531" @default.
• W2059583192 abstract "Objective: To compare the efficacy and safety of ciprofloxacin otic solution 0.2% to polymyxin B-neomycin-hydrocortisone (PNH) otic solution in the treatment of acute diffuse otitis externa in children, adolescents, and adults.Methods: This was a randomized, parallel-group, evaluator-blind, active-controlled, multicenter, noninferiority study. The primary efficacy endpoint was clinical cure of otitis symptoms at the test-of-cure (TOC) visit. Clinical cure at the end-of-treatment (EOT) visit and percentages of patients with clinical improvement and resolution and/or improvement of otalgia at EOT and TOC visits were secondary efficacy endpoints.Results: A total of 630 patients were randomized to ciprofloxacin twice daily (n = 318) or PNH 3 times daily (n = 312) for 7 days. Ciprofloxacin was shown to be noninferior to PNH. The percentage of patients with clinical cure at the TOC visit was 86.6% with ciprofloxacin and 81.1% with PNH; the treatment difference was 5.6% in favor of ciprofloxacin (95% CI: −0.9 to 12.1). At the EOT visit, clinical cure was achieved in 70.0% and 60.5% of patients, respectively, with a treatment difference in favor of ciprofloxacin (9.5%, 95 CI: 1.2 to 17.9). In all secondary efficacy variables, ciprofloxacin and PNH showed similar results, including pain duration and resolution. The clinical cure rate for patients with baseline cultures showing P. aeruginosa was 87.5% in the ciprofloxacin group and 78.6% in the PNH group, a treatment difference of 8.9% in favor of ciprofloxacin (95% CI: 0.6 to 17.3); for patients with baseline cultures showing S. aureus, the clinical cure rate was 72.7% for the ciprofloxacin group and 75.9% for the PNH group (treatment difference of 3.1% in favor of PNH, 95% CI: −21.1% to 27.4%). Most adverse events were mild and unrelated to study medication in both treatment groups. A limitation of this study is the assessment of signs and symptoms at baseline and after treatment, which does not provide data to evaluate the interim response.Conclusions: Ciprofloxacin otic solution 0.2% was found to be noninferior to PNH. This efficacy, good tolerability, and ease of administration make ciprofloxacin otic solution 0.2% without a topical steroid an attractive option for the treatment of acute otitis externa." @default.
• W2059583192 created "2016-06-24" @default.
• W2059583192 creator A5001445287 @default.
• W2059583192 creator A5032535811 @default.
• W2059583192 creator A5037539800 @default.
• W2059583192 creator A5044576161 @default.
• W2059583192 creator A5045813683 @default.
• W2059583192 creator A5046436764 @default.
• W2059583192 date "2008-11-18" @default.
• W2059583192 modified "2023-09-26" @default.
• W2059583192 title "Comparison of efficacy and safety of ciprofloxacin otic solution 0.2% versus polymyxin B-neomycin-hydrocortisone in the treatment of acute diffuse otitis externa" @default.
• W2059583192 cites W1547493004 @default.
• W2059583192 cites W1969535434 @default.
• W2059583192 cites W1985933892 @default.
• W2059583192 cites W1992756895 @default.
• W2059583192 cites W1995753136 @default.
• W2059583192 cites W1999302204 @default.
• W2059583192 cites W2001028523 @default.
• W2059583192 cites W2008040853 @default.
• W2059583192 cites W2029899341 @default.
• W2059583192 cites W2040781991 @default.
• W2059583192 cites W2051081446 @default.
• W2059583192 cites W2078001265 @default.
• W2059583192 cites W2078711214 @default.
• W2059583192 cites W2080984895 @default.
• W2059583192 cites W2081075970 @default.
• W2059583192 cites W2093664920 @default.
• W2059583192 cites W2094956788 @default.
• W2059583192 cites W2100750517 @default.
• W2059583192 cites W2107735508 @default.
• W2059583192 cites W2126069489 @default.
• W2059583192 cites W2133308029 @default.
• W2059583192 cites W2163398872 @default.
• W2059583192 cites W2167036679 @default.
• W2059583192 cites W2411523386 @default.
• W2059583192 cites W2418680845 @default.
• W2059583192 cites W2439004981 @default.
• W2059583192 cites W4231990859 @default.
• W2059583192 cites W4255294947 @default.
• W2059583192 doi "https://doi.org/10.1185/03007990802583845" @default.
• W2059583192 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19032135" @default.
• W2059583192 hasPublicationYear "2008" @default.
• W2059583192 type Work @default.
• W2059583192 sameAs 2059583192 @default.
• W2059583192 citedByCount "20" @default.
• W2059583192 countsByYear W20595831922012 @default.
• W2059583192 countsByYear W20595831922013 @default.
• W2059583192 countsByYear W20595831922014 @default.
• W2059583192 countsByYear W20595831922016 @default.
• W2059583192 countsByYear W20595831922018 @default.
• W2059583192 countsByYear W20595831922019 @default.
• W2059583192 countsByYear W20595831922020 @default.
• W2059583192 countsByYear W20595831922021 @default.
• W2059583192 crossrefType "journal-article" @default.
• W2059583192 hasAuthorship W2059583192A5001445287 @default.
• W2059583192 hasAuthorship W2059583192A5032535811 @default.
• W2059583192 hasAuthorship W2059583192A5037539800 @default.
• W2059583192 hasAuthorship W2059583192A5044576161 @default.
• W2059583192 hasAuthorship W2059583192A5045813683 @default.
• W2059583192 hasAuthorship W2059583192A5046436764 @default.
• W2059583192 hasConcept C126322002 @default.
• W2059583192 hasConcept C141071460 @default.
• W2059583192 hasConcept C168563851 @default.
• W2059583192 hasConcept C203092338 @default.
• W2059583192 hasConcept C2776439223 @default.
• W2059583192 hasConcept C2778512257 @default.
• W2059583192 hasConcept C501593827 @default.
• W2059583192 hasConcept C535046627 @default.
• W2059583192 hasConcept C71924100 @default.
• W2059583192 hasConcept C86803240 @default.
• W2059583192 hasConcept C89423630 @default.
• W2059583192 hasConcept C90924648 @default.
• W2059583192 hasConceptScore W2059583192C126322002 @default.
• W2059583192 hasConceptScore W2059583192C141071460 @default.
• W2059583192 hasConceptScore W2059583192C168563851 @default.
• W2059583192 hasConceptScore W2059583192C203092338 @default.
• W2059583192 hasConceptScore W2059583192C2776439223 @default.
• W2059583192 hasConceptScore W2059583192C2778512257 @default.
• W2059583192 hasConceptScore W2059583192C501593827 @default.
• W2059583192 hasConceptScore W2059583192C535046627 @default.
• W2059583192 hasConceptScore W2059583192C71924100 @default.
• W2059583192 hasConceptScore W2059583192C86803240 @default.
• W2059583192 hasConceptScore W2059583192C89423630 @default.
• W2059583192 hasConceptScore W2059583192C90924648 @default.
• W2059583192 hasIssue "12" @default.
• W2059583192 hasLocation W20595831921 @default.
• W2059583192 hasLocation W20595831922 @default.
• W2059583192 hasOpenAccess W2059583192 @default.
• W2059583192 hasPrimaryLocation W20595831921 @default.
• W2059583192 hasRelatedWork W1586374228 @default.
• W2059583192 hasRelatedWork W2003938723 @default.
• W2059583192 hasRelatedWork W2047967234 @default.
• W2059583192 hasRelatedWork W2089201504 @default.
• W2059583192 hasRelatedWork W2118496982 @default.
• W2059583192 hasRelatedWork W2364998975 @default.
• W2059583192 hasRelatedWork W2369162477 @default.
• W2059583192 hasRelatedWork W2439875401 @default.
• W2059583192 hasRelatedWork W4238867864 @default.

• next